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Epstein–Barr virus (EBV)-associated gastric carcinomas (GC) represent a distinct and well-
recognized subtype of gastric cancer with a prevalence of around 10% of all GC. In contrast,
EBV has not been reported to play a major role in esophageal adenocarcinomas (EAC) and
adenocarcinomas of the gastro-esophageal junction (GEJ). We report our experiences on
EBV in collections of gastro-esophageal adenocarcinomas from two surgical centers and
discuss the current state of research in this field.Tumor samples from 465 primary resected
gastro-esophageal adenocarcinomas (118 EAC, 73 GEJ, and 274 GC) were investigated.
Presence of EBV was determined by EBV-encoded small RNAs (EBER) in situ hybridization.
Results were correlated with pathologic parameters (UICC pTNM category, Her2 status,
tumor grading) and survival. EBER positivity was observed in 14 cases. None of the EAC
were positive for EBER. In contrast, we observed EBER positivity in 2/73 adenocarcinomas
of the GEJ (2.7%) and 12/274 GC (4.4%). These were of intestinal type (seven cases) or
unclassifiable (six cases), while only one case was of diffuse type according to the Lauren
classification. No association between EBV and pT, pN, or tumor grading was found, neither
was there a correlation with clinical outcome. None of the EBER positive cases were Her2
positive. In conclusion, EBV does not seem to play a role in the carcinogenesis of EAC.
Moreover, adenocarcinomas of the GEJ show lower rates of EBV positivity compared to
GC. Our data only partially correlate with previous reports from the literature. This high-
lights the need for further research on this distinct entity. Recent reports, however, have
identified specific epigenetic and genetic alterations in EBV-associated GC, which might
lead to a distinct treatment approach for this specific subtype of GC in the future.
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INTRODUCTION
The presence of Epstein–Barr virus (EBV) in a subset of gastric car-
cinomas (GC) was first reported in 1990 (1). Today, it is recognized
that EBV-associated GC show distinct molecular alterations sug-
gesting a specific tumorigenesis pathway. Morphologically, EBV
positivity was first described in lymphoepithelioma-like GC. In
this particular histological subtype, the prevalence of EBV positiv-
ity is observed in more than 90% of cases (2–4). EBV can also be
detected in carcinomas with conventional histology, namely, with
diffuse or intestinal type according to the Lauren classification and
all show an increased amount of tumor infiltrating lymphocytes
(2, 4, 5).
Although approximately 5–20% of GC are found to be asso-
ciated with EBV (2, 4, 6, 7), the prevalence of EBV in other
gastrointestinal adenocarcinomas of the upper gastrointestinal
tract, such as esophageal adenocarcinomas (EAC) and adenocar-
cinomas of the gastro-esophageal junction (GEJ) seems to be far
less important (8, 9).
In this paper, we report our experiences on the role, frequency,
and possible prognostic and biologic impact of EBV in gastro-
esophageal adenocarcinomas in collections of primary resected
tumors from two surgical centers and discuss our findings in the
context of the current state of research in this field.
MATERIALS AND METHODS
PATIENTS AND TISSUES
Formalin-fixed, paraffin-embedded (FFPE) archival cancer tissue
from 118 patients with EAC (i.e., AEG I according to Siewert)
(10), 73 patients with adenocarcinomas of GEJ (i.e., AEG II and
AEG III according to Siewert) (10), and 274 patients with GC
who underwent primary surgery between 1995 and 2005 at the
Klinikum Rechts der Isar of the Technische Universität München,
Germany (GEJ and GC), and between 1990 and 2011 at the Insel-
spital Bern, Switzerland (EAC). None of the patients had received
pre- or perioperative neoadjuvant treatment. TNM-staging was
performed according to the UICC/AJCC system 7th edition (11)
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Table 1 | Comparison of clinicopathological characteristics of
esophageal adenocarcinomas, adenocarcinomas of the
gastro-esophageal junction and gastric carcinomas.
EAC GEJ GC
Gender Male 102 51 170
Female 16 22 104
pT category pT1 36 4 20
pT2 26 5 26
pT3 51 29 84
pT4 5 35 144
pN category pN0 58 18 67
pN1 19 27 82
pN2 22 19 95
pN3 19 9 30
Distant metastases Absent 113 61 198
Present 5 12 76
Grading G1 18 0 1
G2 51 12 42
G3 49 61 231
Lauren classification Intestinal 101 40 112
Mixed 12 12 48
Diffuse 3 16 96
Non-classifiable 2 5 18
EAC, esophageal adenocarcinomas; GEJ, gastro-esophageal junction; GC, gastric
carcinomas.
and histopathological grading was done in accordance to the WHO
(12). The pathologic features of the case collections are given in
Table 1. Follow-up data (overall survival) were available from 397
patients. The use of archival tissue for research was approved by
the local ethical commissions.
EBER IN SITU HYBRIDIZATION
EBV-encoded small RNAs (EBER) in situ hybridization for the
detection of EBV infection was performed as described before
(13) and applied on tissue microarrays (TMA). The TMAs have
already been used in several studies (GEJ and GC cases) (14) or
were recently constructed (EAC cases). The TMAs contained three
1.0 mm cores per case (GEJ, GC) or six 0.6 mm cores per case
(EAC), each from different tumor regions.
Freshly cut (3µm) slides were deparaffinized, and endoge-
nous peroxidase activity was quenched by incubation in 1% H2O2
in methanol. Slides were washed in ethanol and air-dried. The
sections were incubated with an EBER probe (DAKO Cytoma-
tions, Glostrup, Denmark) for 90 min at 55°C or with PBS for
negative controls. Immunodetection was then performed with
the Labvision (Labvision, Fremont, CA, USA) detection system
and visualized with 5-bromo-4-chloro-3-indolyl-phosphate. For
negative controls, the EBER probe was omitted.
Her2 ANALYSIS (IMMUNOHISTOCHEMISTRY AND FLUORESCENCE
IN SITU HYBRIDIZATION)
Data for Her2 in GC and adenocarcinomas of the GEJ were
obtained from a previous study (14). In brief, for FISH analysis,
an assay with fluorescence-labeled locus-specific DNA probes
for Her2 and chromosome-17 (CEP17) centromeric α-satellite
(Chrombios) was hybridized onto 4µm TMA sections. The
evaluation of FISH signals was performed by visual counting
using an epifluorescence microscope (Zeiss Axioplan, Carl Zeiss
Microimaging GmbH) according to current recommendations
(15). Amplification was diagnosed when Her2/CEP17 quotient
was>2.
For immunohistochemistry, dewaxed and rehydrated slides
were incubated with an antibody against Her2 (DAKO, Glostrup,
DK), following heat-induced antigen retrieval using 10 mm citrate
buffer, pH 6, H2O2 blocking using 3% H2O2 in distilled water
and avidin biotin blocking (Avidin/Biotin blocking kit, Vector
Laboratories, Inc., Burlingame, CA, USA). Positive and nega-
tive controls were included in each reaction. Assessment of Her2
expression by immunohistochemistry (scores 0 to 3+) was done
according to published recommendations (16). Her2 status was
defined as Her2 3+ immunoreaction or Her2 2+ with additional
detection of amplification by FISH (according to the EMEA/FDA
criteria) (17).
STATISTICAL ANALYSIS
For statistical analysis, IBM SPSS 21.0 Statistics statistical soft-
ware (SPSS Inc., Chicago, IL, USA) was used. Associations between
EBER-ISH and pathological features as well as immunohistochem-
ical expression patterns and FISH results, respectively, were given
in crosstabs and were evaluated with X 2 and Fisher’s exact tests.
Survival analysis was done using Kaplan–Meier estimates and log
rank tests. All tests were two-sided, and the significance level was
set at 0.05.
RESULTS
EBV DETECTION IN GASTRO-ESOPHAGEAL ADENOCARCINOMAS
EBV-encoded small RNAs positivity was observed in 14 cases in
total. None of the EAC were positive for EBER. In contrast, we
observed EBER positivity in 2/73 adenocarcinomas of the GEJ
(2.7%) and 12/274 GC (4.4%). One case of GC showed EBER
positivity only in the accompanying lymphocytic infiltrate but not
in the tumor cells. In positive cases, all tumor cells showed pos-
itive staining, and showed no intratumoral heterogeneity across
the different TMA cores.
CORRELATION WITH CLINIC-PATHOLOGIC FEATURES
EBV-encoded small RNAs positive cases were of intestinal type
(seven cases) according to the Lauren classification, while only one
case was of diffuse type. Six cases were unclassifiable according to
the Lauren classification, but these tumors showed the characteris-
tic lymphoepithelioma-like carcinoma morphology. Interestingly,
the one EBV negative case with the EBV positive lymphoid infil-
trate showed this particular pattern as well. Selected examples of
EBV positive GC are shown in Figure 1.
An association between EBV and pT category, pN category, or
tumor grading was not found neither was there any correlation
with patient’s clinical outcome.
The pathologic features of all EBER positive cases are given in
Table 2.
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FIGURE 1 | Examples of EBER staining patterns and morphology in
gastric carcinomas. (A,B) “Lymphoepithelioma-like” morphology; EBER
positive [(A) HE; (B) EBER-ISH], (C,D) “intestinal type” morphology, EBER
positive [(C) HE; (D) EBER-ISH]; (E,F) “lymphoepithelioma-like” morphology;
EBER negative in the tumor, but positive in accompanying lymphocytic
infiltrate [(E) HE; (F) EBER-ISH]; (G,H) “intestinal type” morphology, EBER
negative [(G) HE; (H) EBER-ISH] (EBER, EBV-encoded small RNAs; ISH,
in situ hybridization).
Table 2 | Clinicopathological characteristics of all EBER positive cases.
Patient Gender Age Local pT pN pM R-status Grading Lauren class
1 F 70 GEJ 3 0 0 0 3 Intestinal
2 M 70 GEJ 4 4 0 1 2 Intestinal
3 M 75 GC 1 0 0 0 2 Intestinal
4 M 84 GC 2 0 0 0 3 Non-classifiable
5 F 85 GC 1 0 0 0 3 Non-classifiable
6 M 63 GC 1 1 0 0 3 Intestinal
7 F 78 GC 3 1 0 0 3 Non-classifiable
8 M 52 GC 3 2 0 0 3 Intestinal
9 M 64 GC 4 3 1 2 3 Intestinal
10 M 68 GC 4 3 0 1 3 Diffuse
11 M 42 GC 4 3 1 2 3 Non-classifiable
12 M 50 GC 3 3 0 0 3 Non-classifiable
13 F 75 GC 4 4 0 0 3 Intestinal
14 F 74 GC 3 4 0 0 3 Non-classifiable
GEJ, gastro-esophageal junction; GC, gastric carcinomas; Local, localization; R-status, resection status; EBER, EBV-encoded small RNAs.
EBV AND Her2 IN GASTRIC CARCINOMAS AND ADENOCARCINOMAS
OF THE ESOPHAGOGASTRIC JUNCTION
Results of the EBER analysis for GC and adenocarcinomas of the
GEJ were also compared with data for Her2 expression and ampli-
fication from a previous study (see above). Her2 data were available
from 336 cases. Of these, 36 tumors (10.7%) were classified as Her2
positive according to the FDA criteria described above. The EBER
positive tumors were all negative for Her2 (Table 3).
DISCUSSION
PREVALENCE OF EBV IN GASTRO-ESOPHAGEAL CANCER
Since its first description, EBV-associated GC has emerged as a
distinct subtype of GC, with an average prevalence of almost 10%.
The frequency of detection of EBV, however, varies between 5 and
20%, which may depend on the patient collections in different
Table 3 | Association between Her2 and Epstein–Barr virus in gastric
cancer.
Her2 status Total
Negative Positive
EBV Negative 286 36 322
Positive 14 0 14
Total 300 36 336
studies (2, 4, 6, 7). Geographic differences are discussed as a rea-
son for this variation, although not confirmed in meta-analysis
(4). Of interest, EBV-associated tumorigenesis seems to be rather
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restricted to gastric cancer whereas the role of EBV in other
gastrointestinal carcinomas such as esophageal carcinomas or
small and large bowel cancers (9, 13, 18) seems to be negligible.
In the present study, we observed EBV positivity determined
by EBER in situ hybridization in 14/465 cases of upper gastroin-
testinal adenocarcinomas in total. Of interest, none of the EAC
were positive for EBER. This is in line with previous reports where
there was no EBV positivity detected in collections with EAC (8)
or squamous cell carcinomas (9) using EBER in situ hybridization.
The rate of EBER positivity was very low in adenocarcinomas of
the GEJ as well. In true GC, we could demonstrate EBER positivity
in 4.4%, with a predominance of distal carcinomas (10 cases out
of 12). The rate of positive cases in total is lower than expected
from the literature. EBER in situ hybridization is recommended
as a sensitive and specific method of choice for the detection of
EBV in human tissue and tumors (2) and is usually used for the
detection of EBV. Comparable to other studies, we used a TMA
approach. We furthermore had two separate staining reactions for
every case and there was no intratumoral heterogeneity in the
staining patterns, therefore we regard our results of ISH as true
findings. EBER-ISH furthermore allows the accurate localizing of
the infected cells and we clearly could demonstrate the EBER pos-
itivity in the tumor cells. However, we also observed one case with
lymphoepithelioma-like morphology and EBER positivity in the
accompanying lymphocytic infiltrate but not in the carcinoma
cells. Such a finding may explain why some studies have reported
higher false positive rates, namely by interpreting DNA or RNA
results based on extracts from whole slides containing both tumor
and lymphatic tissue rather than exclusively tumor tissue (19, 20).
MORPHOLOGY OF EBV-ASSOCIATED GASTRIC CANCER
Epstein–Barr virus positivity was first described in
lymphoepithelioma-like GC, where its prevalence is extremely
high (over 90%) (2–4). EBV can also be detected in carcino-
mas with conventional histology. Moreover, a higher proportion
of diffuse versus intestinal type of GC according to Lauren clas-
sification has been reported in several studies. Nonetheless, no
significant difference regarding other clinic-pathologic features
could be found between intestinal or diffuse patterns in meta-
analysis (2, 4). In contrast, in our study from a Western pop-
ulation, we found comparable numbers of EBV positive solid,
lymphoepithelioma-like carcinomas (unclassifiable according to
the Lauren classification) and conventional, intestinal type carci-
nomas, which morphologically did not significantly differ from
other intestinal type tumors. In routine diagnostic setting, the
detection of EBV-associated GC may therefore be hampered by
the lack of a specific histologic appearance. In view of potential
therapeutic consequences, which will be discussed later, a broader
usage of EBV testing might be warranted in a future diagnostic
workup of GC.
MOLECULAR GENETICS OF EBV-ASSOCIATED GASTRIC CANCER
It has been shown that the virus remains in an episomal location in
the monoclonal infected tumor cells and that EBER are abundantly
expressed. As already discussed, the gold standard for specific
detection of GC bearing an EBV infection is the performance of
EBER in situ hybridization (2, 5).
The entry of EBV into epithelial cells is more complicated and
inefficient compared to the similar process in B-lymphocytes. In
B-cells, the virus utilizes binding of gp 42 to the human leuko-
cyte antigen class II, whereas epithelial cells lacking HLA class II
require more complex ways involving integrin complexes to reach
the intracellular compartment. Despite those differences, the virus
is able to infect both epithelium and lymphocytes (21–23).
Epstein–Barr virus-associated tumors are strongly correlated
with methylation of CpG islands in the promoter region of cancer-
related genes as well as with genome-wide hypermethylation,
whereas microsatellite instable (MSI) tumors show other hyper-
methylation patterns, suggesting a different mechanism leading to
epigenetic dysregulation in EBV and MSI tumors (24–27). This
assumption is supported by the fact that EBV positivity in GC has
been shown to be mutually exclusive to loss of MLH1 expression
and MSI (28).
In a recent publication, a division into five molecular subtypes
of gastric cancer based on findings of whole genome sequencing
has been proposed. In addition to the well-known histomorpho-
logical subtypes according to the Lauren classification (intestinal,
diffuse, and mixed type), two supplementary molecular subtypes,
MSI and EBV, have been included. Furthermore, the authors
confirm the epigenetic differences between EBV-associated and
MSI GC. The former display low levels of demethylation and
extensive genome-wide hypermethylation, whereas the latter is
characterized on the other hand by broad demethylation and less
hypermethylation (28). The identification of this specific mole-
cular genetic pattern of EBV positive GC was also confirmed in
a second very recent study of the cancer genome atlas (TCGA)
project (29): based on their findings the authors propose a mol-
ecular classification by dividing gastric cancer into four subtypes
(EBV positive, MSI, genomically stable tumors, and chromoso-
mal instable tumors). EBV positive carcinomas show recurrent
PIK3CA mutations, extreme DNA hypermethylation, and ampli-
fication of JAK2, CD274, and PDCD1LG2. Aberrations of the
latter molecules (also known as PD-L1 and PD-L2) may not only
serve for a molecular genetic classification but also as specific
targets for immunotherapy (30, 31). Based on these results, test-
ing for EBV might be warranted for GC in a future diagnostic
setting.
Another potential therapeutically relevant marker, Her2, which
is overexpressed or amplified in a significant subset of gastro-
esophageal adenocarcinomas and which is regarded as a predictive
marker for anti-Her2 targeted therapy (32), has been shown to be
less expressed in EBV-associated GC compared to EBV negative
GC (33–36). Supplementary to this data, which originate from
Asian patient collectives, we could not detect any Her2 positive
cases in the group of EBV-associated carcinomas. Our study is the
first to analyze the correlation of Her2 and EBV in gastric cancer
in a Western population. The reliability of our data was moreover
increased by assessing the Her2 status according to the EMEA/FDA
guidelines.
EBV-ASSOCIATED GASTRIC CANCER AND CLINIC-PATHOLOGIC
FEATURES
In EBV positive GC, the proportion of male gender has reported to
be significantly higher in contrast to female patients (2, 4, 7), which
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we also could observe in our case collection. The prognostic rel-
evance of EBV infection in GC has not been clearly elucidated so
far. Most studies describe a favorable prognosis with improved
survival and lower rate of lymph node metastases in patients
with EBV-associated GC compared to EBV negative GC. A recent
meta-analysis supports these findings, reporting lower tumor and
lymph node stages according to TNM classification as well as a
lower rate of distant metastases. EBV positivity was further asso-
ciated with lower mortality rate when adjusted for stage and other
confounders (37). However, another meta-analysis exhibited con-
tradictory results, reporting no association of EBV positivity with
depth of tumor invasion, lymph node metastases, or clinical stage
(2), which is in line with our observations: we could not detect an
association between EBV and pT category, pN category, or tumor
grading, neither was there a correlation with clinical outcome of
the patients in our case collection.
The EBV status of carcinoma cells does not influence current
therapeutic schemes (7), but the recent molecular genetic find-
ings may raise the question whether EBV positivity could act as
a predictive marker in GC and lead to novel therapeutic options.
Indeed, in different studies EBV positive GC were associated with
chemoresistance against various cytotoxic drugs (38, 39). Since
our case collection consisted of primary resected tumors only, we
could not demonstrate any correlation between tumor regression
and EBV status in the present study. However, there are data about
the successful use of specific drug combinations in order to over-
come the resistance to conventional chemotherapeutics, which
also might influence neoadjuvant or other multimodal therapy
concepts (38, 40). The mechanisms involved in this process need
to be better understood, in order to implement specific treatment
options for this subgroup of GC.
SUMMARY
In conclusion, we could demonstrate the presence of EBV by
EBER in situ hybridization in a subset of gastric cancers and also
in a small number of adenocarcinomas of the GEJ. In contrast,
EBV does not seem to play a role in the carcinogenesis of EAC.
However, the data from our case collections only partially corre-
late with previous reports from the literature. This highlights the
need for further research on this distinct entity. The pathogenetic
role of EBV in carcinogenesis is still poorly understood and the
presence of EBV has no therapeutic implication at present. Most
recent reports, however, identified different genetic and epigenetic
alterations in EBV-associated GC compared to viral negative GC.
Targeting the viral infection itself or molecules deregulated within
this specific molecular background might lead to a distinct treat-
ment approach in future perspectives and might also influence
routine diagnosis of gastric cancer with regard to detection of
EBV positive cases.
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